Related Experiment Videos
[Gene therapy by in vivo interferon-gamma gene transfer to murine bladder tumor]
1Department of Urology, Faculty of Medicine, Kyoto University.
Abstract:
For the clinical application of the cytokine gene therapy, the antitumor effects of systemic administration of Interferon-gamma (IFN-gamma) and those of in vivo direct IFN-gamma gene transfer to the tumors of mouse bladder carcinoma (MBT2) were compared. After the subcutaneous inoculation of MBT2 cells into mice, 10(2), 10(3) or 10(4) units of IFN-gamma were injected intraperitoneally (i.p.) or subcutaneously (s.c.). Neither i.p. nor s.c. injection of IFN-gamma resulted in tumor suppression or prolonged the survival time of tumor-bearing mice. The effect of in vivo direct IFN-gamma gene transfer by a retrovirus vector to MBT2 tumors was also evaluated. After the subcutaneous inoculation of MBT2 cells into mice, a virus culture supernatant containing IFN-gamma gene was injected into the same tumor site once a day for 3 days. In 50% of the mice in the treatment groups with IFN-gamma gene induction, no tumor formation was observed. Tumor-free survival and actuarial survival in the treatment groups were significantly longer than those in the control group. These results showed the possibility of in vivo direct IFN-gamma gene transfer into tumors and were encouraging for the execution of tumor cell-targeted IFN-gamma gene therapy against human bladder cancer.
Insights
Direct gene transfer of Interferon-gamma (IFN-gamma) into mouse bladder tumors showed significant antitumor effects, unlike systemic IFN-gamma injections. This cytokine gene therapy approach offers promise for future bladder cancer treatments.
Area of Science:
- Oncology
- Gene Therapy
- Immunology
Background:
- Cytokine gene therapy is a potential strategy for cancer treatment.
- Interferon-gamma (IFN-gamma) has known immunomodulatory and antitumor properties.
- Evaluating delivery methods for IFN-gamma is crucial for clinical application.
Purpose of the Study:
- To compare the antitumor efficacy of systemic Interferon-gamma (IFN-gamma) administration versus direct in vivo IFN-gamma gene transfer.
- To assess the potential of targeted IFN-gamma gene therapy for mouse bladder carcinoma (MBT2).
Main Methods:
- Comparison of intraperitoneal (i.p.) and subcutaneous (s.c.) systemic IFN-gamma injections in MBT2 tumor-bearing mice.
- In vivo direct gene transfer of IFN-gamma using a retrovirus vector into MBT2 tumors.
- Evaluation of tumor suppression, tumor-free survival, and actuarial survival rates.
Main Results:
- Systemic administration of IFN-gamma (i.p. or s.c.) did not suppress MBT2 tumor growth or prolong survival.
- Direct in vivo IFN-gamma gene transfer resulted in no tumor formation in 50% of treated mice.
- Significant improvements in tumor-free and actuarial survival were observed in the direct gene transfer groups compared to controls.
Conclusions:
- Direct in vivo gene transfer of IFN-gamma demonstrates potent antitumor activity against mouse bladder carcinoma.
- Systemic administration of IFN-gamma is ineffective for this tumor model.
- Targeted IFN-gamma gene therapy holds promise for clinical application in human bladder cancer.